Myeloma - A to Z
Mutiple myeloma is a type of cancer that develops from cells in the bone marrow called plasma cells. Almost 4,000 cases of multiple myeloma are diagnosed every year in the UK.
We do not know what causes mutiple myeloma. It is most likely to affect people over 40 and risk increases with age. It is also about twice as common in black people as it is in white. Certain rare medical conditions can increase the risk of developing the cancer.
Cancer Research UK is funding research to understand how and why myeloma develops in the bone marrow. We also fund clinical trials testing new treatments for the disease. .
Browse content about Myeloma
- News story: Scientists identify first genetic link to myeloma
27 November 2011 - News story: NICE recommends bortezomib and thalidomide for multiple myeloma
26 August 2010 - News story: NICE approves lenalidomide for multiple myeloma patients who have received previous treatments
24 June 2009 - News story: Protein regulates tumour cell growth in multiple myeloma
11 September 2007 - News story: NICE recommends innovative funding scheme for Velcade
4 June 2007 - Press Release: Proof that controversial therapy is effective
7 May 2003
- News story: Trial drug 'effective' against cancers with faulty BRAF gene
26 August 2010 - News story: Green tea may reduce risk of some cancers
15 October 2009 - News story: NICE confirms Velcade decision
25 October 2007 - News story: NICE guidance recommends innovative funding scheme for Velcade
30 August 2007 - News story: Mould by-product could lead to new myeloma drug
17 April 2007
